Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 14INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Chemoembolization, Therapeutic × Clear all
NCT04231929 2022-03-28

BIOPEARL-FIRST

Terumo Europe N.V.

Phase NA Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT02548780 2020-01-27

LifePearl-Doxo Pharmacokinetic (PK) Study

Terumo Europe N.V.

Phase NA Completed
15 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡